Xencor reported $41.2M in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Alexion Pharmaceuticals ALXN:US $ 3429.6M 465.1M
Alnylam Pharmaceuticals ALNY:US $ 1093.99M 348.22M
Amgen AMGN:US $ 11969M 5339M
Arrowhead Research ARWR:US $ 184.43M 141.55M
AstraZeneca AZN:LN 7067M 8500M
Biogen BIIB:US $ 1541.8M 200.2M
Bristol Myers Squibb BMY:US $ 13540M 2516M
Cytokinetics CYTK:US $ 477.64M 440.48M
Epizyme EPZM:US $ 124.52M 44.35M
GlaxoSmithKline GSK:LN 3453M 50M
Karyopharm Therapeutics KPTI:US $ 137.4M 3.91M
Macrogenics MGNX:US $ 190.53M 1.56M
Novartis NOVN:VX SF 7211M 2094M
Regeneron Pharmaceuticals REGN:US $ 3432.4M 1360.2M
Seattle Genetics SGEN:US $ 685.17M 271.74M
Xencor XNCR:US $ 41.2M 74.64M